[Carbapenem restriction reduce the incidence of multidrug-resistant Acinetobacter baumannii in ventilator associated pneumonia]
- PMID: 19374793
[Carbapenem restriction reduce the incidence of multidrug-resistant Acinetobacter baumannii in ventilator associated pneumonia]
Abstract
Objective: To determine the relation of carbapenem restriction with the incidence of multidrug-resistant (MDR) Acinetobacter baumannii in ventilator associated pneumonia (VAP).
Methods: Twenty-six patients admitted to the intensive care unit, West China Hospital, Sichuan University, from June to December in 2007, with confirmed VAP were randomized to two groups: conventional group (14 cases) and carbapenem restriction group (12 cases). All sputum samples were collected throughout the trial. The correlation between the incidence of MDR Acinetobacter baumannii and the consumption of carbapenem was analyzed.
Results: The incidence of MDR Acinetobacter baumannii (10.7%, 7/65) and consumption of carbapenem (61 g) in carbapenem restriction group were significantly lower than conventional group (17.8%, 13/73, 188 g, both P<0.05). The result implied that the decreased incidence of MDR Acinetobacter baumannii was attributable to the reduction of carbapenem consumption.
Conclusion: Carbapenem constraint could reduce the incidence of MDR Acinetobacter baumannii in VAP.
Similar articles
-
Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan.J Microbiol Immunol Infect. 2010 Aug;43(4):323-31. doi: 10.1016/S1684-1182(10)60050-3. J Microbiol Immunol Infect. 2010. PMID: 20688293
-
Identification of multidrug- and carbapenem-resistant Acinetobacter baumannii in Canada: results from CANWARD 2007.J Antimicrob Chemother. 2009 Sep;64(3):552-5. doi: 10.1093/jac/dkp225. Epub 2009 Jul 3. J Antimicrob Chemother. 2009. PMID: 19578083
-
High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii.Scand J Infect Dis. 2007;39(1):38-43. doi: 10.1080/00365540600951184. Scand J Infect Dis. 2007. PMID: 17366011 Clinical Trial.
-
Treatment of Acinetobacter infections.Expert Opin Pharmacother. 2010 Apr;11(5):779-88. doi: 10.1517/14656561003596350. Expert Opin Pharmacother. 2010. PMID: 20210684 Review.
-
Acinetobacter baumannii skin and soft-tissue infection associated with war trauma.Clin Infect Dis. 2008 Aug 15;47(4):444-9. doi: 10.1086/590568. Clin Infect Dis. 2008. PMID: 18611157 Review.
Cited by
-
Intensive care antibiotic consumption and resistance patterns: a cross-correlation analysis.Ann Clin Microbiol Antimicrob. 2017 Nov 13;16(1):71. doi: 10.1186/s12941-017-0251-8. Ann Clin Microbiol Antimicrob. 2017. PMID: 29132352 Free PMC article.
-
Effects of Carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients.Ann Clin Microbiol Antimicrob. 2014 Jan 9;13:7. doi: 10.1186/1476-0711-13-7. Ann Clin Microbiol Antimicrob. 2014. PMID: 24405720 Free PMC article.
-
Carbapenem Restriction and its Effect on Bacterial Resistance in an Intensive Care unit of a Teaching Hospital.Iran J Pharm Res. 2013 Summer;12(3):503-9. Iran J Pharm Res. 2013. PMID: 24250656 Free PMC article.
-
Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital.Infect Drug Resist. 2015 Mar 24;8:31-8. doi: 10.2147/IDR.S78633. eCollection 2015. Infect Drug Resist. 2015. PMID: 25848308 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical